Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA Income Statement 2011-2026 | BPTS

Annual Income Statement Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 549 M - - - - - - - - - -

Shares

- - 118 M - - - - - - - - - -

Historical Prices

0.33 1.43 4.64 - - - - - - - - - -

Net Income

- - -31.2 M -17.1 M -17.8 M -14 M -11.4 M -7.95 M -3.29 M -709 K -522 K - -

Operating Income

- - -26.8 M -13.9 M -15.7 M -13.9 M - - - - - - -

EBITDA

- - -26.8 M -13.9 M -15.7 M -13.9 M -9.7 M -7.77 M -3.12 M -659 K -468 K - -

General and Administrative Expenses

- - 7.15 M 4.02 M 4.6 M 4.35 M 2.86 M 2.82 M 2.07 M 373 K 396 K - -

All numbers in EUR currency

Quarterly Income Statement Biophytis SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in EUR currency

The income statement is one of the three key financial reports of a company Biophytis SA (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.63 -4.4 % $ 191 M usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.73 -0.03 % $ 33.4 M israelIsrael
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.83 -5.21 % $ 214 M israelIsrael
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.12 - $ 649 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Exelixis Exelixis
EXEL
$ 51.1 -0.37 % $ 13.9 B usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 23.96 -2.84 % $ 310 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 8.9 0.56 % $ 1.08 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 4.4 -7.76 % $ 1.31 B canadaCanada
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 17.3 -5.57 % $ 809 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.99 -0.26 % $ 22.2 B germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
$ 3.03 6.32 % $ 283 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 132.06 -0.74 % $ 164 B usaUSA
Genmab A/S Genmab A/S
GMAB
$ 26.9 1.32 % $ 1.74 B danmarkDanmark
Genprex Genprex
GNPX
$ 0.86 1.2 % $ 802 K usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.49 -4.12 % $ 5.75 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.79 1.04 % $ 5.29 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.3 3.14 % $ 64.2 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 21.57 -0.55 % $ 2.74 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 9.24 36.48 % $ 264 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA